Medicare open enrollment has begun, and beneficiaries must navigate significant changes to health and prescription drug coverage in 2027. These changes include increased Part D cost thresholds and new prices for popular medications.
Enrollment Period Details
The annual Medicare open enrollment period is from October 15 to December 7. During this time, beneficiaries can compare current coverage with other options, such as original Medicare, Medicare Advantage plans, and prescription drug plans. Selections made will start on January 1.
Cost Increases for 2027
Escalating Part D Costs
The out-of-pocket threshold for Medicare Part D will rise to $2,400 in 2027. This represents a $300 increase from 2026. The standard Part D deductible will also increase from $615 to $700. Such increases could diminish the purchasing power of seniors, despite a 3.6 percent Social Security cost-of-living adjustment.
“A 14 percent increase in Medicare Part D’s out-of-pocket cap and another 14 percent increase in the standard deductible will wipe away some of the purchasing power seniors receive from their 3.6 percent Social Security COLA,” stated Kevin Thompson, CEO of 9i Capital Group.
End of Part D Premium Stabilization
The Centers for Medicare & Medicaid Services (CMS) will discontinue the Part D Premium Stabilization Demonstration, returning to traditional market conditions. Although some seniors might experience slight increases in premiums, plan specifics will vary.
The national base beneficiary premium for 2027 will be $41.33, but premiums will depend on individual plans. An ongoing premium stabilization provision caps increases at 6 percent annually through 2029.
Drug Pricing and Additional Changes
Medicare-Negotiated Drug Prices
In 2027, negotiated prices for 15 more high-cost drugs will take effect. This includes medications like Ozempic and Wegovy, potentially reducing costs for beneficiaries by approximately $685 million.
Medications involved in the negotiation include Trelegy, Ellipta, Xtandi, Pomalyst, Ibrance, Ofev, Linzess, Calquence, Austedo and Austedo XR, Breo Ellipta, Tradjenta, Xifaxan, Vraylar, Janumet and Janumet XR, and Otezla.
Changes in Medicare Advantage Plans
Some Medicare Advantage insurers may withdraw from certain areas or modify benefits, affecting coverage options. As a result, seniors should carefully review their coverage before the enrollment deadline.
“While negotiated prices on major medications could provide significant savings, others may face higher premiums or reduced benefits. Seniors must review their coverage carefully,” advised Alex Beene, a financial literacy instructor.
Key Considerations for Beneficiaries
As beneficiaries review plans, they should focus on:
- Monthly premiums and any changes
- Drug deductibles and copays
- Supplemental benefits, which may decrease
The increased cost pressures highlight the need for thorough evaluation of Medicare options during open enrollment, which concludes on December 7. New coverage starts January 1, placing responsibility on consumers to manage healthcare expenses effectively.
